Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Full Circle: Allergan's Revenue Growth Fuels Reinvestment In Sales, R&D

trading

Related Content

Actavis will become Allergan to emphasize branded pharma focus

Feb 19 2015

What does Actavis get in $66bn Allergan buy?

Nov 18 2014

With Parion Deal Done, Shire CEO Looks To Next Bright Ophthalmic Innovation

May 02 2017

1Q Pharma Results Preview: Merck, Pfizer, Gilead, Novo Nordisk, Shire, Allergan, Teva

Apr 29 2017

Forest's Saunders ropes 2nd major sale, boosts personal brand in Actavis deal

Feb 19 2014

Editas Deal Opens Allergan's Eyes To CRISPR Opportunities

Mar 14 2017

Allergan Pays $2bn-Plus For Zeltiq, Expanding Aesthetics Business

Feb 13 2017

Meet The New Teva: 8% Global Generics Share, 300 ANDAs, 1,500 Launches

Sep 15 2016

Related Companies

Allergan plc

ZELTIQ Aesthetics, Inc.

Teva Pharmaceutical Industries Ltd.

Takeda Pharmaceutical Co. Ltd.

Editas Medicine

Allergan plc

Forest Laboratories, Inc.

Allergan plc

Additional Topics

Sales & Earnings Companies Business Strategies Commercial BioPharmaceutical

More from Earnings

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window